Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02275-x, published online 3 April 2023
In the version of the article initially published, in the “Toxicity analysis” section, “Nine patients (25%) discontinued all therapy as a result of AEs” has been corrected to “Five patients (13.8%)…”. In the fifth paragraph of the Discussion, “9 patients (25%) discontinued therapy as a result of AEs” has been removed and “25%” has been changed to “13.8%” in the text “Of note is a higher rate of AE-related treatment discontinuation of 13.8%”. These changes have been made to the HTML and PDF versions of the article.
Change history
08 July 2024
The version of the correction initially published did not mention the second correction to the Discussion (changing 25% to 13.8%) and has now been amended.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saba, N.F., Steuer, C.E., Ekpenyong, A. et al. Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial. Nat Med 30, 2373 (2024). https://doi.org/10.1038/s41591-024-03161-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-024-03161-w
